OnKure Therapeutics (NASDAQ:OKUR) Now Covered by Leerink Partners

Leerink Partners assumed coverage on shares of OnKure Therapeutics (NASDAQ:OKUR) in a research report released on Thursday morning, MarketBeat.com reports. The firm issued an outperform rating and a $33.00 price objective on the stock.

Other research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of OnKure Therapeutics in a report on Friday, November 8th. Lifesci Capital upgraded OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, October 10th. Finally, Oppenheimer began coverage on OnKure Therapeutics in a research report on Thursday, October 10th. They set an “outperform” rating and a $35.00 price target on the stock. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, OnKure Therapeutics has an average rating of “Buy” and an average target price of $36.00.

OnKure Therapeutics Stock Down 0.3 %

Shares of OKUR opened at $14.16 on Thursday. OnKure Therapeutics has a 52 week low of $9.80 and a 52 week high of $77.60. The stock has a market capitalization of $47.29 million, a P/E ratio of -1.16 and a beta of 0.14. The business has a 50-day moving average of $16.77.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.13). Equities research analysts expect that OnKure Therapeutics will post -4.21 EPS for the current fiscal year.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.